

3 April 2024

Treatment of Myeloproliferative Neoplasms

Q1. Please provide the total number of patients treated in the last 6 months for:

The Trust is unable to provide the number of patients treated in the last 6 months for the below conditions. We can provide the number of individuals admitted to hospital with a Primary Diagnosis as listed below for the time period 1 July 2023 to 31 December 2023.

- **Polycythaemia Vera (ICD10 code D45) =** Individuals 17, Admissions 53.
- **Myelofibrosis (ICD10 code D47.4) =** Individuals 10, Admissions 13.
- **Myelofibrosis (ICD10 code D47.4) patients aged 65 and older =** Individuals 7, Admissions 10.

Note:

- The number of admissions may be higher than the number of individuals as patients may be admitted to hospital a number of times during the time period.
- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. How many patients were treated in the past 6 months (for any disease) with:

21/09/23 – 21/03/24

- Ruxolitinib = 34 Patients
- Fedratinib = <5 Patient
- Momelotinib = <5 Patients

Q3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:

21/09/23 – 21/03/224

- Ruxolitinib = 19 Patients
- Fedratinib = <5 Patient
- Momelotinib = <5 Patients

3 April 2024

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

The numbers of individuals admitted to hospital as a day case or elective with a Primary Diagnosis as listed below for the time period 1 April 2020 to 31 March 2023.

Individuals 23, Admissions 67.

Note:

- The number of admissions may be higher than the number of individuals as patients may be admitted to hospital a number of times during the time period.
- **Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?**
- **Of these patients, how many were treated in the past 6 months with Interferon therapy?**
- **Of these patients, how many have received no active treatment in the past 6 months?**

Belfast Trust does not hold this information centrally. To retrieve it would require a manual trawl of individual patient records. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

FEDORA- A phase II study to evaluate the tolerability, safety and activity of Fedratinib combined with Ropeninterferon Alfa-2b in patients with myelofibrosis.
– 1 patient recruited now off treatment.

PROMise - Investigation into the combination of PLX2853 with Ruxolitinib in patients with Intermediate-2 or High Risk Myelofibrosis not receiving an adequate response with Ruxolitinib alone.
– 2 patients recruited.